DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA379590
Title:
Evaluation of Drug and Vaccine Candidates in the Human Malaria/Aotus Monkey Model
Descriptive Note:
Annual rept. 1 Mar 1999-28 Feb 2000
Corporate Author:
PROMED TRADING S A MIAMI FL
Report Date:
2000-03-01
Pagination or Media Count:
37.0
Abstract:
A C2A clone of a Mefloquine resistant Plasmodium faiciparum strain was successfully adapted to splenectomized and intact Aotus. Chioroquine resistance reversal was achieved in 33 Aotus infected with the AMRU-1 strain of Plasmodium vivax by using chloroquine at 1Omgkg and prochiorperazine at 20 mgkg in combination. Artelinic Acid WR255663AKBM041 31 when given orally at 2 mgkg x three days suppressed infections of the AMRU-1 CQR but cleared SAL-1 strains of P. vivax in Aotus monkeys. Artelinic Acid WR255663AKBM04131 administered orally at 2-24 mgkg x three days was effective against infections of P. falciparum FVO strain in Aotus monkeys. Orally or intravenously administered falcipain APC33l 7 was ineffective against infections of P. falciparum FVO. Artelinic Acid and Artesunate were effective against infections with P. falciparum FVO in Aotus monkeys. Passive transfer of anti-EBA-175 Region II protein monoclonal antibodies was not effective at controlling parasitemia in Aotus monkeys infected with P. falciparum. Immunization with a plasmid encoding region ll of EBA-1 75 followed with by a EBA-175 recombinant protein boost partially protected Aotus monkeys against P. falciparum malaria. Topical ocular administration of a plasmid DNA vaccine encoding an AMA-1 P. falciparum blood stage antigen did not induce an immune response in Aotus monkeys.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
